SYNVISC® Clinical Efficacy
Long Lasting OA Knee Pain Relief
SYNVISC® provides long-lasting relief for up to 6 months for chronic OA knee pain1
The SYNVISC family delivers maximum duration of relief for chronic OA knee pain among currently approved viscosupplements.1, 3-14, 17
View additional study details ›
SYNVISC® demonstrated rapid OA knee pain relief as early as week 1 and up to 26 weeks with significant improvement from baseline1,17,a
In the pivotal clinical trial, significant pain reduction from baseline occurred 1 week after the first injection of SYNVISC and lasted through 26 weeks, as assessed by blinded evaluators.1,17,a
WEIGHT-BEARING PAIN: PATIENT ASSESSMENT17, b
See SYNVISC/Synvisc-One study details ›
Safety
- AEs related to SYNVISC were reported for 2.2% of injections and 7.2% of patients after a single course of treatment17
- Most commonly reported device-related AEs with SYNVISC: pain in injected knee, swelling in injected knee, and joint effusion17
- No severe AEs were observed in the SYNVISC group
Synvisc-One® (hylan G-F 20) is the only single-injection viscosupplement to show superiority vs saline in reducing pain at 6 months in a randomized clinical study2,4-5,18,19
Synvisc-One demonstrated significantly greater improvement in OA knee pain than saline control in the pivotal clinical trial.2,18,b,c
See SYNVISC/Synvisc-One study details ›
References
- Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410-423.
- Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69(1):113-119.
- Gel-One [prescribing information]. Warsaw, IN: Zimmer USA; 2011.
- Monovisc summary of safety and effectiveness data. Silver Spring, MD: US Food and Drug Administration; 2014.
- Durolane [instructions for use]. Durham, NC: Bioventus LLC; 2017.
- Euflexxa [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; 2016.
- Orthovisc [prescribing information]. Raynham, MA: DePuy Mitek Inc; 2005.
- Hyalgan [prescribing information]. Parsippany, NJ: Fidia Pharma USA Inc; 2014.
- Supartz FX [prescribing information]. Durham, NC: Bioventus LLC; 2015.
- Hymovis [prescribing information]. Parsippany, NJ: Fidia Pharma USA Inc; 2015.
- GenVisc 850 [prescribing information]. Doylestown, PA: OrthogenRx Inc; 2015.
- Gelsyn-3 [prescribing information]. Pambio-Noranco, Switzerland: Institut Biochimique SA; 2016.
- Visco-3 [prescribing information]. Durham, NC: Bioventus LLC; 2016.
- TriVisc [prescribing information]. Doylestown, PA: OrthogenRx Inc; 2017.
- Caborn D, Rush J, Lanzer W, Parenti D, Murray C. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2):333-343.
- Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee—a prospective randomized clinical trial. Knee. 2008;15(4):318-324.
- SYNVISC [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
- Synvisc-One [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
- Gel-One summary of safety and effectiveness data. Silver Spring, MD: US Food and Drug Administration; 2016.
